Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism

Endocrinology

Volumn 144, Issue 5, 2003, Pages 2000-2007

  Lotinun, Sutada ^a   Sibonga, Jean D ^a   Turner, Russell T ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; COMPLEMENTARY DNA; CYTOKINE; CYTOKINE RECEPTOR; MESSENGER RNA; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TETRACYCLINE; TRAPIDIL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET-DERIVED GROWTH FACTOR A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE TURNOVER; CONTROLLED STUDY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; MAST CELL; MYELOFIBROSIS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PARATHYROID DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; ANIMAL; METABOLISM; NASA DISCIPLINE CELL BIOLOGY; NON-NASA CENTER; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

NASA DISCIPLINE CELL BIOLOGY; NON-NASA CENTER;

ANIMALS; BONE DISEASES; FEMALE; HYPERPARATHYROIDISM; PARATHYROID HORMONE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRAPIDIL;

EID: 0037733118     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-221000     Document Type: Article

References (46)

1. Bereket A, Casur Y, Firat P, Yordam N 2000 Brown tumour as a complication of secondary hyperparathyroidism in severe long-lasting vitamin D deficiency rickets. Eur J Pediatr 159:70-73
2. Kulak CA, Bandeira C, Voss D, Sobieszczyk SM, Silverberg SJ, Bandeira F, Bilezikian JP 1998 Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab 83:732-735
3. Khosla S, Melton 3rd LJ, Wermers RA, Crowson CS, O'Fallon W, Riggs B 1999 Primary hyperparathyroidism and the risk of fracture: a population-based study J Bone Miner Res 14:1700-1707
4. Silverberg SJ, Bilezikian JP 2001 Clinical presentation of primary hyperparathyroidism in the United States. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. 2nd ed. San Diego: Academic Press; 349-360
5. Mithal A, Bandeira F, Meng X, Silverberg SJ, Shi Y, Mishra SK, Griz L, Macedo G, Celdas G, Bandeira C, Bilezikian JP, Rao SD 2001 Clinical presentation of primary hyperparathyroidism: India, Brazil, and China. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. 2nd ed. San Diego: Academic Press; 375-386
6. Rosenberg AE 1994 Skeletal system and soft tissue tumors. In: Cotran RS, Kumar V, Robbins SL, eds. Pathologic basis of disease. Philadelphia: Saunders; 1213-1272
7. Rubin E, Farber JL 1994 The endocrine system. In: Rubin E, Farber JL, eds. Pathology. 2nd ed. Philadelphia: Lippincott; 1098-1147
8. Coburn JW, Henry DA 1984 Renal osteodystrophy. Adv Intern Med 30:387-424
9. Schiller AL, Teitelbaum SL 1990 Bones and joints. In: Rubin E, Farber JL, eds. Pathology. 3rd ed. Philadelphia: Lippincott-Raven; 1336-1413
10. Coburn JW, Salusky IB 2001 Renal bone diseases: clinical features, diagnosis and management. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. 2nd ed. San Diego: Academic Press; 635-661
11. Dobnig H, Turner RT 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612
12. Tiell ML, Sussman II, Gordon PB, Saunders RN 1983 Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, trapidil. Artery 12:33-50
13. Gocer AI, Polat S, Ozel S, Tuna M, Kaya M, Cetinalp E, Haciyakupoglu S 1998 The effect of trapidil on the reactive astrocytic proliferation following spinal cord trauma in rats: light and electron microscopic findings. Neurol Res 20:365-373
14. Futamura A, Izumino K, Nakagawa Y, Takata M, Inoue H, Iida H 1999 Effect of the platelet-derived growth factor antagonist trapidil on mesangial cell proliferation in rats. Nephron 81:428-433
15. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
16. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
17. Poon M, Cohen J, Siddiqui Z, Fallon JT, Taubman MB 1999 Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Lab Invest 79:1369-1375
18. Deguchi J, Abe J, Makuuchi M, Takuwa Y 1999 Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery. Life Sci 65:2791-2799
19. Jerome CP, Gubler HP 1991 Experimental determination of the "the law of bone remodeling" and effect of rat parathyroid hormone (1-34) infusion on derived parameters. Calcif Tissue Int 49:398-402
20. Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, Zanelli JM 1983 Effects of two treatment regimens with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112:1000-1006
21. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE 1994 Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogerdtor cells in bone marrow. Bone 15:717-723
22. Betsholtz C, Johnsson A, Heldin C-H, Westermark B, Lind P, Urdea MS, Eddy R, Shows TB, Philpott K, Mellor AL, Knott TJ, Scott J 1986 cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature 320:695-699
23. Heldin C-H, Westermark B 1987 PDGF-like growth factors in autocrine stimulation of growth. J Cell Physiol 5(Suppl):S31-S34
24. sis of simian sarcoma virus. Nature 304:35-39
25. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF 1989 Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem 264:8771-8778
26. Heldin C-H, Westermark B 1996 Role of platelet-derived growth factor in vivo. In: Clark RAF, eds. The molecular and cellular biology of wound repair. 2nd ed. New York: Plenum Press; 249-273
27. Raines EW, Bowen-Pope DF, Ross R 1990 Platelet-derived growth factor. In: Sporn, MB, Robert AB, eds. Handbook of experimental pharmacology. Peptide growth factors and their receptors. Heidelberg: Springer-Verlag; 173-262
28. Lotinun S, Sibonga JD, Turner RT 2002 Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17:29-36
29. Hiragun T, Morita E, Tanaka T, Kameyoshi Y, Yamamoto S 1998 A fibrogenic cytokine, platelet-derived growth factor (PDGF), enhances mast cell growth indirectly via a SCF- and fibroblast-dependent pathway. J Invest Dermatol 111:213-217
30. Johansson C, Roupe G, Lindstedt G, Mellstrom D 1996 Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25:1-7
31. Hsieh SC, Graves DT 1998 Pulse application of platelet-derived growth factor enhances formation of a mineralizing matrix while continuous application is inhibitory. J Cell Biochem 69:169-180
32. Peart KM, Ellis HA 1975 Quantitative observations on iliac bone marrow mast cells in chronic renal failure. J Clin Pathol 28:947-955
33. Nakamura M, Kuroda H, Narita K, Endo Y 1996 Parathyroid hormone induces a rapid increase in the number of active osteoclasts by releasing histamine from mast cells. Life Sci 58:1861-1868
34. Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T 1992 Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 123:1439-1444
35. Mazurov AV, Menshikov M, Yu Leytin VL, Tkachuk VA, Repin VS 1984 Decrease of platelet aggregation and spreading via inhibition of cAMP phosphodiesterase by trapidil. FEBS Lett 172:167-171
36. 2. Prostaglandins Med 6:269-281
37. Zhou L, Ismaili J, Stordeur P, Thielemans K, Goldman M, Pradier O 1999 Inhibition of CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol 93:232-238
38. Bonisch D, Weber AA, Wittpoth M, Osinski M, Schror K 1998 Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Mol Pharmacol 54:241-248
39. Kinoshita T, Kobayashi S, Ebara S, Yoshimara Y, Horiuchi H, Tsutsumimoto T, Wakabayashi S, Takaoka K 2000 Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27:811-817
40. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC 2002 Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282:1-17
41. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ 2000 Fibroblast stromal cells express receptor activator of NF-κB ligand and support osteoblast differentiation. J Bone Miner Res 15:1459-1466
42. Nilsson G, Svensson V, Nilsson K 1995 Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1. Scand J Immunol 42:76-81
43. Centrella M, McCarthy TL, Kusmik WF, Canalis E 1991 Relative binding and biochemical effects of heterodimeric and homodimeric isoforms of platelet-derived growth factor in osteoblast-enriched cultures from fetal rat bone. J Cell Physiol 147:420-426
44. Pfeilschifter J, Krempien R, Naumann A, Gronwald RG, Hoppe J, Ziegler R 1992 Differential effects of platelet-derived growth factor isoforms on plasminogen activator activity in fetal rat osteoblasts due to isoform-specific receptor functions. Endocrinology 130:2059-2066
45. Hock JM, Canalis E 1994 Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 134:1423-1428
46. Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Kumagai A 1981 A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factor. Life Sci 28:1641-1646